Randox Biosciences - The key to success in CDx

Dr Claire Huguet of Randox Biosciences explains how precise antibody selection is enabling companion diagnostics (CDx) to drive the development of personalised medicine.

Companion diagnostics (CDx) represent a major step forward in the development of precision medicine. These enable a novel drug to be prescribed only to the patients expressing a marker of interest in relation to the drug mechanism. Due to their primary use in oncology, the focus so far has been on molecular and tissue-based assays. However, with personalised medicine principles extending to therapeutic areas beyond cancer treatment, and with the realisation of the potential of liquid biopsies, the interest for antibody-based CDx is growing fast.

Know your enemy

What will make the next CDx immunoassays successful, then, with so many assays already available and the race to generate the antibodies against novel targets accelerating in the market?

Intimate knowledge of the disease's biology has proved crucial to developing novel therapeutic molecules, and in-depth understanding of the best antibody target will permit the CDx immunoassays of the future to define the patient population eligible for a given treatment.

On the right path

The journey starts at the immunisation level, engineering the most appropriate hapten to favour an antibody response of the highest specificity for the molecular target. Ideally, the latter must be robust enough to ensure good marker stability in patient samples.

This means understanding the degradation pathways that will affect the target in the bloodstream, within the body and at pre-analytical stages.

Avoid risk

It should also be highly preserved between species, so that the same antibody raised against a human protein target can show high cross-reactivity for the same target in animal samples, avoiding the need for antibody remake, and relating bridging studies, between pre-clinical and clinical assessment of the candidate biomarker. This also means avoiding the risk of being unable to reproduce in the clinic the signal that was observed in the early stages of the drug development.

Stay on target

The molecular target for the antibody should also take into account the various biological entities that may interfere in the anitibody binding and generate inaccurate signals - with a clear understanding that consequences for the patient may have to include assessing whether or not they receive a life-critical medication.

Selecting highly repeated motifs can help increase the assay sensitivity, while the need to target hardly accessible epitopes will benefit from experience with antibody fragment technology.

Make it personal

Certainly, the final antibody selection and the quality of the assay development stages will also affect the ultimate performance of the immunoassay released for testing. However, it is the molecular targeting steps, and the ability to selectively elicit the appropriate antibody specificity, that will make a difference in the appropriateness of the assay to be raised as a CDx.

Selective hapten engineering and custom antibody development have been among Randox Biosciences' strengths for many years, and it is proud contribute to personalised medicine strategies as they unfold.

Products and Services

Contact Details

Randox Biosciences
55 Diamond Road Crumlin
Co. Antrim
BT29 4QY
United Kingdom
Tel: +44 (0) 28 9442 2413
Email: info@randoxbiosciences.com
URL: www.randoxbiosciences.com

As liquid biopsies begin to reveal their potential, the interest in antibody-based CDx is growing rapidly.
Randox Biosciences draws on three decades’ experience to create personalised, precise and cost-effective diagnostic techniques.
We are the ideal CDx partner; with over 220 FDA-cleared and 700 CE-marked assays, we offer the full package of diagnostic and CDx assay development, optimisation and regulatory approval.
Biochip Array Technology is an innovative multiplex testing platform that facilities the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
Randox Biosciences provides an extensive range of off-the-shelf and custom antibodies and recombinant proteins.
Make An Enquiry
First Name

Last Name

Email Address


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.